RE:Accelerated Approval and Priority Review.The really good thing about this Fast-Track Approval, is that now I'm confident we have enough cash to see this through to commercialization. Would certainly like to see a report on how many have been treated since the study was opened up again, but we might have to wait for the Q4 Progress Report, which would come early January. If we can hold a base around this level I doubt we will see many looking for Tax-Loss Selling. Some BIg Investors might of already closed those positions when we were hanging out at 13 for a few months.